[VIRTUAL] Triglycerides, Icosapent for Non-Triglyceride Risk Reduction and Lp (AACE 2021) - May 16, 2021 - Pres time: May 28, 2021; 05:55 PM - 06:15 PM; "Learning Objectives: Assess the key differences between REDUCE-IT and STRENGTH CV Outcomes Trials Select patients in whom pure prescription EPA (icosapent ethyl) has been proven to reduced CVD (all of the following): (a) At high CVD risk (prior event or DM2+ other risk factors) (b) Taking a statin (c) With controlled LDL-C, but with (d) Residual TG-elevation (> 135 mg/dL)Implement the use of pure prescription EPA (icosapent ethyl) in CVD prevention in these selected patients"
|
|
Eliot A. Brinton, MD, FAHA, FNLA, FACE
|